ScaleReady awards a G-Rex® Grant to Moonlight Bio
ScaleReady, along with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a G-Rex® Grant to Moonlight Bio to support their CAR T cell therapy development for solid tumors. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.
The grant provides Moonlight Bio with access to a commercial CAR T manufacturing platform, funding for IND-enabling studies validation runs, Bio-Techne's ProPak™ and GMP Cytokines, and optional analysis of manufacturing batch records by CellReady. Individual grants are worth up to $300,000.
Moonlight Bio's technology is based on research published in Nature, focusing on enhancing engineered T cell therapies by utilizing mutations from T cell malignancies.
ScaleReady, insieme a Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) e CellReady, ha assegnato un G-Rex® Grant a Moonlight Bio per supportare lo sviluppo della loro terapia con cellule CAR T per i tumori solidi. Il finanziamento fa parte dell'iniziativa da 20 milioni di dollari di ScaleReady per promuovere lo sviluppo di terapie cellulari e cellule modificate da geni.
Il grant fornisce a Moonlight Bio l'accesso a una piattaforma commerciale per la produzione di CAR T, finanziamenti per le corse di convalida degli studi abilitanti IND, ProPak™ di Bio-Techne e citochine GMP, oltre all'analisi opzionale dei registri di produzione da parte di CellReady. I singoli grant possono arrivare fino a 300.000 dollari.
La tecnologia di Moonlight Bio si basa su ricerche pubblicate su Nature, concentrandosi sul potenziamento delle terapie con cellule T ingegnerizzate tramite l'utilizzo di mutazioni derivanti da neoplasie delle cellule T.
ScaleReady, junto con Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) y CellReady, ha otorgado un G-Rex® Grant a Moonlight Bio para apoyar el desarrollo de su terapia celular CAR T para tumores sólidos. La subvención es parte de la iniciativa de ScaleReady de 20 millones de dólares para avanzar en el desarrollo de terapias celulares y células modificadas genéticamente.
La subvención proporciona a Moonlight Bio acceso a una plataforma comercial de fabricación de CAR T, financiamiento para las corridas de validación de estudios habilitantes IND, ProPak™ de Bio-Techne y citoquinas GMP, junto con un análisis opcional de los registros de lotes de fabricación por parte de CellReady. Las subvenciones individuales tienen un valor de hasta 300,000 dólares.
La tecnología de Moonlight Bio se basa en investigaciones publicadas en Nature, enfocándose en mejorar las terapias con células T ingenierizadas al utilizar mutaciones de malignidades de células T.
ScaleReady는 Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), 그리고 CellReady와 함께 Moonlight Bio에 G-Rex® Grant를 수여하여 고형 종양에 대한 CAR T 세포 치료 개발을 지원합니다. 이 기금은 세포 및 유전자 수정 세포 치료 개발을 촉진하기 위한 ScaleReady의 2천만 달러 이니셔티브의 일환입니다.
이 보조금은 Moonlight Bio에게 상업용 CAR T 제조 플랫폼 접근권과 IND 승인 연구의 검증 진행을 위한 자금을 제공하며, Bio-Techne의 ProPak™ 및 GMP 사이토카인, CellReady에 의한 제조 배치 기록 선택적 분석을 포함합니다. 개별 보조금은 최대 30만 달러의 가치가 있습니다.
Moonlight Bio의 기술은 Nature에 발표된 연구를 기반으로 하며, T 세포 악성 종양의 돌연변이를 활용하여 공학적 T 세포 치료를 향상시키는 데 중점을 두고 있습니다.
ScaleReady, en collaboration avec Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) et CellReady, a accordé un G-Rex® Grant à Moonlight Bio pour soutenir le développement de leur thérapie par cellules CAR T pour les tumeurs solides. La subvention fait partie de l'initiative de 20 millions de dollars de ScaleReady pour faire avancer le développement des thérapies cellulaires et des cellules modifiées par des gènes.
La subvention permet à Moonlight Bio d'accéder à une plateforme commerciale de fabrication de CAR T, de financer des études de validation pour des études IND, d'utiliser le ProPak™ de Bio-Techne et des cytokines GMP, ainsi qu'une analyse optionnelle des enregistrements de lots de fabrication par CellReady. Les subventions individuelles peuvent aller jusqu'à 300 000 dollars.
La technologie de Moonlight Bio est basée sur des recherches publiées dans Nature, mettant l'accent sur l'amélioration des thérapies par cellules T ingénieries en utilisant des mutations provenant de malignités des cellules T.
ScaleReady hat zusammen mit Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH) und CellReady einen G-Rex® Grant an Moonlight Bio vergeben, um die Entwicklung ihrer CAR-T-Zelltherapie für solide Tumoren zu unterstützen. Der Zuschuss ist Teil von ScaleReadys Initiative in Höhe von 20 Millionen US-Dollar zur Förderung der Entwicklung von Zell- und genmodifizierten Zelltherapien.
Der Zuschuss ermöglicht es Moonlight Bio, auf eine kommerzielle CAR-T-Herstellungsplattform zuzugreifen, Mittel für die Validierungsläufe von IND-Studien zu erhalten, ProPak™ von Bio-Techne sowie GMP-Cytokine zu nutzen und optional eine Analyse der Herstellungsbatch-Aufzeichnungen durch CellReady durchzuführen. Einzelne Zuschüsse sind bis zu 300.000 US-Dollar wert.
Die Technologie von Moonlight Bio basiert auf in Nature veröffentlichten Forschungen, die sich darauf konzentrieren, die entwickelten T-Zelltherapien durch die Nutzung von Mutationen aus T-Zell-Malignitäten zu verbessern.
- Part of a significant $20M initiative in cell and gene therapy development
- Grant provides access to commercial manufacturing platform and validation funding
- Includes access to Bio-Techne's new closed system reagent solutions
- None.
Insights
The G-Rex Grant awarded to Moonlight Bio represents a significant milestone in advancing CAR T cell therapy development. The grant, valued up to
The grant's impact extends beyond financial support - it provides access to Bio-Techne's ProPak™ and GMP Cytokines, along with CellReady's manufacturing expertise. This comprehensive support package significantly reduces development timelines and manufacturing costs, two critical factors in cell therapy commercialization. The technology's focus on solid tumors, a challenging area for CAR T therapy, could potentially expand treatment options for cancer patients.
This strategic grant program, part of ScaleReady's
The partnership structure minimizes upfront investment while maintaining exposure to promising therapeutic developments. The focus on cost-effective, scalable manufacturing solutions addresses a critical industry bottleneck, positioning Bio-Techne favorably in the competitive CGT space.
"We are grateful to receive a G-Rex Grant to support the advancement of our lead CAR T asset into the clinic in a platform that is cost effective and scalable. This mechanism is a creative solution that provides access to expertise and a highly efficient manufacturing platform to biotechnology companies in a way that saves significant time and money," said Dr. Jordan Jarjour, Chief Scientific Officer at Moonlight Bio.
"I'm confident that Moonlight Bio will quickly find out that ScaleReady's expertise and the G-Rex Grant Program will preserve the two most precious commodities for any cell therapy entity, time and money," said John Wilson, CEO of Wilson Wolf Manufacturing and co-inventor of G-Rex.
Moonlight Bio's technology is based on a recent article published in Nature from the labs of two of their scientific co-founders, Dr. Kole Roybal and Dr. Jaehyuk Choi, that describes a unique approach to enhance engineered T cell therapies by co-opting mutations that naturally occur in T cell malignancies (PMID: 38326614). By screening dozens of mutations from T cell neoplasms, their results indicate that exploiting naturally occurring mutations represents a promising approach to discover how solutions derived from the selective process of cancer evolution can improve T cell therapies.
As part of the G-Rex Grant, ScaleReady will provide Moonlight Bio access to a commercially viable CAR T manufacturing platform. The G-Rex Grant may also be used to defray the cost associated with validation runs to support the IND-enabling studies for Moonlight's lead CAR T asset. Additionally, Moonlight Bio will get access to Bio-Techne's new closed system reagent solutions, ProPak™ and GMP Cytokines for simplification of cytokine delivery. Finally, Moonlight Bio will have the option to receive a complimentary analysis of their master manufacturing batch records by CellReady, the world's first and only G-Rex centric contract development and manufacturing organization, to ensure commercial viability of the manufacturing process.
ScaleReady's G-Rex Grant Program is a
For more information about the G-Rex® Grant Program, please contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Moonlight Bio, Inc.
Moonlight Bio, Inc. is a preclinical-stage biotechnology company based in
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-awards-a-g-rex-grant-to-moonlight-bio-302334680.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of individual G-Rex Grants awarded by Bio-Techne (TECH) and partners?
What benefits does the G-Rex Grant provide to Moonlight Bio?
How does the G-Rex Grant Program support cell therapy development?
What is the total value of ScaleReady's G-Rex Grant Program initiative?
